Somatic Genome Editing in Cardiovascular Disease: Platforms, Targets, and Translational Progress

Somatic genome editing may provide durable treatment for selected cardiovascular diseases, but its translational maturity is organ-dependent. This narrative review compares CRISPR-Cas nucleases, base editors, and prime editors across liver-directed and direct myocardial applications, with emphasis on target biology, delivery, genomic integrity, clinical evidence, and long-term governance. Liver-directed editing of PCSK9, ANGPTL3, and TTR has produced sustained pharmacodynamic effects after one administration in early clinical studies; these findings establish target engagement, not yet reductions in cardiovascular events, reversal of amyloid cardiomyopathy, or lifelong safety. Direct myocardial editing remains preclinical. MYH7 and MYBPC3 studies demonstrate variant-specific disease prevention in selected neonatal or presymptomatic models, but do not establish reversal of mature hypertrophy, fibrosis, dysfunction, or arrhythmia in adult human myocardium. The principal translational divide therefore reflects the convergence of validated target direction, accessible delivery, measurable systemic output, and tolerable editing heterogeneity in the liver, versus the need for allele-selective, spatially distributed correction in an electrically and mechanically coupled heart. We propose an organ-specific translational evidence framework that separates evidence required before first-in-human administration from evidence generated during clinical development. Progress will depend on clinically meaningful outcomes, cell- and region-resolved editing, product-specific genomic safety, credible management of persistent harm, and durable surveillance.

Authors

Publication Details

Journal
Cardiogenetics
Published
2026-11-18
DOI
https://doi.org/10.3390/cardiogenetics16040027
Primary Topic
CRISPR and Genetic Engineering
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Somatic Genome Editing in Cardiovascular Disease: Platforms, Targets, and Translational Progress

Francesca Gorini, Andrea Borghini, Mariangela Palazzo, Jalil Daher et al.
1 links
Cardiogenetics
CRISPR and Genetic Engineering
article

Somatic Genome Editing in Cardiovascular Disease: Platforms, Targets, and Translational Progress

Francesca Gorini, Andrea Borghini, Mariangela Palazzo, Jalil Daher, George Khawli
article en

Abstract

Somatic genome editing may provide durable treatment for selected cardiovascular diseases, but its translational maturity is organ-dependent. This narrative review compares CRISPR-Cas nucleases, base editors, and prime editors across liver-directed and direct myocardial applications, with emphasis on target biology, delivery, genomic integrity, clinical evidence, and long-term governance. Liver-directed editing of PCSK9, ANGPTL3, and TTR has produced sustained pharmacodynamic effects after one administration in early clinical studies; these findings establish target engagement, not yet reductions in cardiovascular events, reversal of amyloid cardiomyopathy, or lifelong safety. Direct myocardial editing remains preclinical. MYH7 and MYBPC3 studies demonstrate variant-specific disease prevention in selected neonatal or presymptomatic models, but do not establish reversal of mature hypertrophy, fibrosis, dysfunction, or arrhythmia in adult human myocardium. The principal translational divide therefore reflects the convergence of validated target direction, accessible delivery, measurable systemic output, and tolerable editing heterogeneity in the liver, versus the need for allele-selective, spatially distributed correction in an electrically and mechanically coupled heart. We propose an organ-specific translational evidence framework that separates evidence required before first-in-human administration from evidence generated during clinical development. Progress will depend on clinically meaningful outcomes, cell- and region-resolved editing, product-specific genomic safety, credible management of persistent harm, and durable surveillance.

CardiogeneticsVol. 16(4)
Good health and well-being
CRISPR and Genetic Engineering
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon